



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

| | |
|---------------|------------------------|
| Last Trade: | 2.28 |
| Trade Time: | 8:00 PM ET 05/21/18 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 1.42 - 4.37 |
| Volume | 8,145 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 05/15/18**
[Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage](#)
- 05/07/18**
[Rexahn Reports First Quarter 2018 Financial Results](#)
- 04/26/18**
[Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)
- 03/13/18**
[Rexahn Pharmaceuticals to Present at Two Upcoming Conferences](#)
- 03/12/18**
[Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- 03/09/18**
[Annual Report \(10-K\)](#)
- 04/23/18**
[Proxy Statement \(DEF 14A\)](#)
- 05/04/18**
[Quarterly Report \(10-Q\)](#)
- 11/03/17**
[Quarterly Report \(10-Q\)](#)
- 08/04/17**
[Quarterly Report \(10-Q\)](#)